What is Cullinan Oncology Inc Annual Net Profit?

Cullinan Oncology Inc Annual Net Profit fell 9.28% in the last year to $167.38 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

What is Cullinan Oncology Inc Price to Earning Ratio?

Cullinan Oncology Inc Price to Earning Ratio is -2.56, which is negative.

What is Cullinan Oncology Inc Stock Price?

Cullinan Oncology Inc Stock Price fell 56.99% and underperformed its sector by 53.24% in the past year.

What is Cullinan Oncology Inc Quarterly Net profit?

Cullinan Oncology Inc Quarterly Net profit fell 100.17% YoY to $47.65 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

What is Cullinan Oncology Inc Debt to Equity Ratio?

Cullinan Oncology Inc Debt to Equity Ratio is zero as the company is debt-free.

What is Cullinan Oncology Inc Return on Equity(ROE)?

Cullinan Oncology Inc Return on Equity(ROE) for the last financial year was -32.06%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Cullinan Oncology Inc Mutual Fund Holding?

Cullinan Oncology Inc Mutual Fund Holding decreased by 1.66% in the last quarter to 34.61.

What is Cullinan Oncology Inc Institutional Holding?

Cullinan Oncology Inc Institutional Holding remained the same in the last quarter at 119.48%.

How is the Cullinan Oncology Inc today?

The Cullinan Oncology Inc today is trading in the green, up by 0.97% at 7.32.

How has Cullinan Oncology Inc performed historically?

The Cullinan Oncology Inc is currently trading up 0.97% on an intraday basis in the past week the index fell -3.30%. The index has been down -36.68% in the past quarter and fell -56.99% in the past year. You can view this in the overview section.

Cullinan Oncology Inc XNAS: CGEM

Cullinan Oncology Inc Live Share Price Today, Share Analysis and Chart

Name: Cullinan Oncology Inc: Is Infosys Ltd. worth buying?
Item: Cullinan Oncology Inc
Rating: 0.82283325
Author: Trendlyne DVM scores

Download real time

7.32 0.07 (0.97%)

New 52W Low in past week

804.7K XNAS Volume

XNAS 08 Apr, 2025 5:30 PM (EDT)

Cullinan Oncology Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	428.3
PE TTM Negative PE TTM Unavailable in chosen country	-2.6
PEG TTM High in industry Unavailable in chosen country	0.3
Price to Book Below industry Median Unavailable in chosen country	0.7
Institutional holding current Qtr % High in industry Unavailable in chosen country	119.5
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-100.2
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-9.3
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-29.8
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-32.1
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-30.3

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

11.3 / 100

Technically Bearish

21.6 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Cullinan Oncology Inc Stock Price Analysis

Day Price Range 1.0% 1 Day return Unavailable in chosen country	7.3 (LTP) 7.27.8 LowHigh
Week Price Range -3.3% 1 Week return Unavailable in chosen country	7.3 (LTP) 6.87.8 LowHigh
Month Price Range -16.0% 1 Month return Unavailable in chosen country	7.3 (LTP) 6.89.4 LowHigh
52 Week Price Range -57.0% 1 Year return Unavailable in chosen country	7.3 (LTP) 6.830.2 LowHigh

View full Share Price History

Cullinan Oncology Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Cullinan Oncology Inc Stock Analysis

Cullinan Oncology Inc stock analysis with key metrics, changes, and trends.

Cullinan Oncology Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$167.38 M	9.28%	negative	Annual Net Profit fell 9.28% in the last year to $167.38 M. Its sector's average net profit growth for the last fiscal year was -32.62%.
Price to Earning Ratio	-2.56	-	negative	Price to Earning Ratio is -2.56, which is negative.
Stock Price	$7.32	-56.99%	negative	Stock Price fell 56.99% and underperformed its sector by 53.24% in the past year.
Quarterly Net profit	$47.65 M	100.17%	negative	Quarterly Net profit fell 100.17% YoY to $47.65 M. Its sector's average net profit growth YoY for the quarter was -47.55%.
Debt to Equity Ratio	-	-	positive	Debt to Equity Ratio is zero as the company is debt-free.
Return on Equity(ROE)	-32.06 %	-32.06%	negative	Return on Equity(ROE) for the last financial year was -32.06%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	34.61 %	-1.66%	negative	Mutual Fund Holding decreased by 1.66% in the last quarter to 34.61.
Institutional Holding	119.48 %	0%	neutral	Institutional Holding remained the same in the last quarter at 119.48%.

VIEW LESS

Loading data..

Cullinan Oncology Inc - Company Profile

What does Cullinan Oncology Inc do?

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Gross Remuneration

2024

Gross Remuneration

Year

Cullinan Oncology Inc Live Share Price Today, Share Analysis and Chart

New 52W Low in past week

Cullinan Oncology Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Cullinan Oncology Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Cullinan Oncology Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Cullinan Oncology Inc Stock Analysis

Cullinan Oncology Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 9.28% in the last year to $167.38 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

Price to Earning Ratio is -2.56, which is negative.

Stock Price fell 56.99% and underperformed its sector by 53.24% in the past year.

Quarterly Net profit fell 100.17% YoY to $47.65 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

Debt to Equity Ratio is zero as the company is debt-free.

Return on Equity(ROE) for the last financial year was -32.06%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 1.66% in the last quarter to 34.61.

Institutional Holding remained the same in the last quarter at 119.48%.

Cullinan Oncology Inc - Company Profile

What does Cullinan Oncology Inc do?

Cullinan Oncology Inc Management structure

Ms. Mary Kay Fenton

Chief Financial Officer and Principal Accounting Officer

Mr. Jeffrey Trigilio

Chief Financial Officer, Treasurer and Principal Accounting Officer

Mr. Nadim Ahmed

Director, President and Chief Executive Officer

Cullinan Oncology Inc Board of directors

Mr. Thomas Ebeling

Independent Director

Mr. David D. Meek

Director

Mr. Stephen W. Webster

Independent Director

Mr. Anthony Rosenberg

Chairman of the Board

Ms. Mary T. Thistle

Director

Mr. Nadim Ahmed

Director, President and Chief Executive Officer

Cullinan Oncology Inc FAQ

How is Cullinan Oncology Inc today?

Cullinan Oncology Inc today is trading in the green, and is up by 0.97% at 7.32.

How has Cullinan Oncology Inc performed historically?

Cullinan Oncology Inc is currently trading up 0.97% on an intraday basis. In the past week the stock fell -3.30%. stock has been down -36.68% in the past quarter and fell -56.99% in the past year. You can view this in the overview section.